PRTK News and Press, Paratek Pharmaceuticals Inc. From 08/03/23

-- NUZYRA ® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022 --Previously Announced Agreement to be Acquired by Gurnet Point Capital and Novo Holdings A/S; Transaction Expected to Close in the Third Quarte...

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievement of a Commercial Milestone for a Total Potential Value of $3.00 per Share Sp...

NEW YORK, NY / ACCESSWIRE / July 12, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Chinook Therapeutics, Inc. (NAS...

2023-07-11 18:25:24 ET Paratek Pharmaceuticals' ( NASDAQ: PRTK ) investor NexPoint Asset Management has sent a demand letter to the clinical-stage biotech to make available its books and records related to its proposed takeover by Gurnet Point Capital. The letter was issued by...

NexPoint Sends Demand Letter for Books and Records to Paratek Pharmaceuticals in Connection with Proposed Acquisition by Gurnet Point Capital PR Newswire Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty DALLAS , July 11, 2023 ...

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones -- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceu...

2023-06-27 13:48:31 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) said that a European Medicines Agency advisory committee has issued a positive opinion on its drug Nuzyra receiving orphan drug status in the treatment of nontuberculous mycobacterial lung disease, or NTM. The antib...

2023-06-27 13:05:04 ET Paratek Pharmaceuticals ( NASDAQ: PRTK ) investor NexPoint Asset Management said that it may vote against the biotech company's planned takeover by Gurnet Point Capital if it determines that sale is not in the interest of stockholders. NexPoint, which says...

BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today a...

NexPoint Asset Management Sends Open Letter to the Board of Paratek Pharmaceuticals Regarding Upcoming Annual Meeting and Proposed Acquisition by Gurnet Point Capital PR Newswire Intends to Withhold Its Votes Against All Three Board Members Up for Election at the Annual Meet...